- GlobeNewswire•6 days ago
Biomarkers of Muscle Damage Demonstrate Improving Trends in Majority of Patients. Biomarker of Key Disease Substrate Demonstrates Improving Trend in All Patients. Safety Data Continue to Show No Infusion-Associated ...
- Investopedia•7 days ago
Amicus Therapeutics reported positive results for its Fabry disease drug, Galafold.
- GlobeNewswire•7 days agoAmicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposium™ 2017
Scientific Findings Reveal that Cellular Damage Alters Trafficking for Key Proteins Involved in Muscle Membrane Integrity and Muscle Repair. Preclinical Studies Demonstrate Reversal of Cellular Damage ...
FOLD : Summary for Amicus Therapeutics, Inc. - Yahoo Finance
Amicus Therapeutics, Inc. (FOLD)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||5.90 x 100|
|Ask||7.13 x 200|
|Day's Range||5.99 - 6.31|
|52 Week Range||4.41 - 9.83|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.24|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|